Breast Cancer Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, and Immunotherapy), By Cancer Type (Hormonal Receptor, HER2+), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Others), and Region Forecast 2020-2031

Breast Cancer Treatment Market size was valued at US$ 16,200 million in 2024 and is expected to reach US$ 28,350 million by 2031, growing at a significant CAGR of 7.6% from 2025-2031. Moreover, the U.S. Breast Cancer Treatment Market is projected to grow significantly, reaching an estimated value of US$ 9,100 million by 2031.

The market is being revolutionized by the developments in precision medicine, early diagnosis, and targeted therapy. One of the most common oncological ailments worldwide, breast cancer continues to fuel increased investment in diagnostics, therapeutics, and supportive facilities. Personalized care regimens, encompassing hormonal treatment, biologics, immunotherapy, and CDK4/6 inhibitors, are the favored modern treatment modalities now to manage heterogeneity of the tumor and optimize survival. The growing intersection of genomic testing and biomarker profiling is allowing oncologists to pinpoint treatable mutations and deliver drugs with improved efficacy and less toxicity. Not only is this patient-specific strategy transforming clinical guidelines, but it is also compelling industry players to revamp pipelines that integrate efficacy, tolerability, and durable disease control.

Increased surveillance, larger screening campaigns, and favorable pay terms are driving early diagnosis in developed economies. Concurrently, expansion markets are experiencing incremental but sustained infrastructure growth that facilitates access to diagnostics and treatment in larger volumes. The pharma industry is concentrating on combination therapy and next-generation agents like ADCs and checkpoint inhibitors that target resistance in HER2+ and triple-negative subtypes of breast cancer.

Additionally, collaborations between leaders in biotech and major pharma are driving commercialization of cutting-edge therapies across the world. Survival rates having improved, long-term control of disease, and quality-of-life issues are stepping forward as drivers for value, shifting the market toward cure beyond remission to survivorship.

Facts & Figures

• Breast cancer was the most prevalent cancer to be diagnosed in women in 157 out of 185 countries in 2022, reflecting its geospatial spread across various geographies.
• It is estimated that 2.3 million women were diagnosed with breast cancer in 2022 and about 670,000 died from the disease.
• Breast cancer affects women of all ages after puberty but age-specific rates increase very sharply with increasing age, especially towards older age. While the majority are attributed to women, an estimated 0.5–1% of all diagnoses of breast cancer are in men.
• Approximately 50% of female breast cancer happens in women with no identified risk factors other than biological sex and age, indicating its multifactorial origin.
• Global statistics underscore wide inequalities in the distribution of disease burden: in high-HDI nations, 1 woman in 12 will develop the disease during her lifetime, whereas in low-HDI nations fewer women develop the disease but more of them die from the disease because care is not always accessible.
• Breast cancer exists in all countries and among all socio-economic groups, making it a priority on the global health system and policy agenda.

Key Developments:

• In June 2025, Fujifilm India launched its CSR initiative 'Find It Early, Fight It Early', aimed at more than 150,000 women in 24 cities. The program is centered on detection through health screenings and awareness workshops in under-served areas where there is stigma surrounding women's health.
• In June 2025, Dharamshila Narayana Superspeciality Hospital launched a state-of-the-art 3D mammography system on Cancer Survivor Month. The launch was accompanied by a free cancer screening initiative and the roll-out of Ayushman Bharat to take diagnostic services across economic strata.
• In May 2025, Arvinas and Pfizer reported crucial Phase 3 trial data from the VERITAC-2 study wherein vepdegestrant monotherapy demonstrated superiority to fulvestrant in ER+/HER2- metastatic breast cancer patients. These findings were identified during ASCO's annual meeting and published in The New England Journal of Medicine.
• In Jan 2025, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) were approved by the FDA for HR-positive, HER2-low or ultralow breast cancer. The approval was based on Priority Review, supported by data from the DESTINY-Breast06 trial presented at ASCO 2024.

Breast Cancer Treatment Market Segmentation:

Based on the therapy:

• Targeted Therapy
  • Abemaciclib
  • Ado-Trastuzumab Emtansine
  • Everolimus
  • Trastuzumab
  • Ribociclib
  • Palbociclib
  • Pertuzumab
  • Olaparib
  • Others
• Hormonal Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Aromatase Inhibitors
  • Estrogen Receptor Down regulators (ERDs)
• Chemotherapy
• Immunotherapy

Targeted therapy is increasingly becoming the backbone of breast cancer treatment, with Trastuzumab emerging as a favorite, particularly among HER2-positive patients. With its mechanism of binding to HER2 receptors, targeted tumor therapy is delivered with minimal damage to normal cells. The drug has transformed survival rates, notably in early and advanced stages of breast cancer, and remains a fundamental component in combination therapies. Its therapeutic efficacy, widespread physician adoption, and on-going research into subcutaneous presentations and biosimilars cement its dominance. Herceptin's clinical and commercial influence remains highly influential in determining the therapy dynamics of this market, with greater awareness, improved diagnostics for the detection of HER2, and availability of reimbursement in the majority of geographies.

Based on the cancer type:

• Hormone Receptor
• HER2+

HER2-positive breast cancer is a biologically aggressive malignancy but has been transformed dramatically by therapeutic advances. Overexpression of the HER2 protein in approximately 20% of breast cancers has been a hint in the past toward limited channels of treatment—but now, with the presence of targeted therapeutics such as Trastuzumab and Pertuzumab, there have been spectacular improvements in disease-free survival. The HER2+ category is being targeted increasingly with dual HER2 blockade strategies, extended adjuvant therapies, and new antibody-drug conjugates. Diagnostic and biomarker testing technologies are enabling timely detection of this subtype, and studies are expanding into HER2-low segments. Combined, these factors drive the HER2+ segment's persistent clinical attention and market pull.

Based on the distribution channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Hospital pharmacies dominate the distribution channel for breast cancer treatments due to their management of complex therapeutic regimens and advanced drug storage. These pharmacies also have a central role to play in dispensing targeted therapies, Immunotherapeutics, and biologics that require clinically managing and intravenous administration. Because most expensive treatments are initiated in hospital facilities often, oncology or multidisciplinary teams’ hospital pharmacies become central organizations for patient access and adherence monitoring. Their facilities also enable intensive oncology treatment, including formulary management, patient education, and clinical trial management.

In addition, hospital pharmacies benefit from institutional pricing, procurement contracts, and patient support schemes, which collectively make hospital pharmacies the most influential channel for this therapeutic market.